With outstanding fundamentals, including top-class universities and hospitals, a government cognizant of the benefits that a robust research-based biopharma industry brings, and straightforward business processes, Singapore has long been a hub for life science companies…
This new issue of China Healthcare and Life Sciences Review (compiled in December 2019) provides a retrospective of the tremendous gains the Chinese healthcare industry made in 2019 while simultaneously anticipating the challenges and opportunities on the horizon in the new…
Long overshadowed by larger and more well-known neighbours, the island of Taiwan is nonetheless cultivating an enviable reputation at the forefront of some of the most innovative trends shaping global healthcare today. From artificial intelligence to blockchain, the…
Thailand is in the midst of an economic transformation with healthcare at its heart. ASEAN’s second largest economy has implemented an ‘Industry 4.0’ policy through which it is attempting to prioritise R&D and innovation in a number of key industries, including…
With optimism and energy pervading the Chinese healthcare landscape, actors of all stripes see new potential and opportunities on the horizon. The heterogeneity of the Chinese market, with its 31 province-level entities offering a variety of market characteristics and needs;…
One of the indisputable economic success stories of the last half century, South Korea now stands as the world’s 11th largest economy, with a reputation for industrial excellence and innovation. As the Korean state shifts its focus towards healthcare and the life sciences…
China is the country it is impossible to ignore and now accounts for a significant share of revenues for most major multinational pharmaceutical companies. Further, any firm sincerely committed to bringing treatments to the greatest number of patients has to be active in…
Through exclusive interviews with the Malaysian Minister of Health as well as the head of the country’s regulatory body – the NPRA – this report examines emerging trends in Malaysian healthcare, with Prime Minister Matahir Mohamad spearheading a bold health policy…
Despite its small population size, Hong Kong has long held a strategic interest for the healthcare and life sciences industries, whether as a testbed for innovative products and service delivery models as a result of its efficient regulatory approval system or as an…
Through interviews with the heads of some of India’s leading domestic pharmaceutical companies, this report delves into the biologics, biosimilars and new chemical entities being developed in India and taken abroad; the nation’s hubs of development and innovation,…
India can claim with some degree of force to be ‘the pharmacy to the world.’ Not only are Indian medicines consumed in the US and EU, but enterprising Indian companies are increasingly looking towards huge underserved developing markets across the globe.…